Search

Your search keyword '"Paris, Laura"' showing total 14 results
Start Over Author "Paris, Laura" Journal blood
14 results on '"Paris, Laura"'

1. Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Author

D’Agostino, Mattia, primary, Bertuglia, Giuseppe, additional, Rota-Scalabrini, Delia, additional, Belotti, Angelo, additional, Morè, Sonia, additional, Corradini, Paolo, additional, Oliva, Stefania, additional, Ledda, Antonio, additional, Grasso, Mariella, additional, Pavone, Vincenzo, additional, Ronconi, Sonia, additional, Vincelli, Iolanda Donatella, additional, Ballanti, Stelvio, additional, Velluti, Cristina, additional, Cellini, Claudia, additional, Gozzetti, Alessandro, additional, Palmas, Angelo D., additional, Gamberi, Barbara, additional, Mancuso, Katia, additional, Paris, Laura, additional, Zambello, Renato, additional, Petrucci, Maria Teresa, additional, Bruno, Benedetto, additional, Musto, Pellegrino, additional, and Gay, Francesca, additional

Published
2024
Full Text
View/download PDF

2. Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Author

Wong, Sandy W., primary, Bar, Noffar, additional, Paris, Laura, additional, Hofmeister, Craig C, additional, Hansson, Markus, additional, Santoro, Armando, additional, Mateos, Maria-Victoria, additional, Rodríguez-Otero, Paula, additional, Lund, Johan, additional, Encinas, Cristina, additional, Yee, Andrew J., additional, Oriol, Albert, additional, Cerchione, Claudio, additional, de la Rubia, Javier, additional, Ferstl, Barbara, additional, Carlson, Kristina, additional, Ribas, Paz, additional, Bermúdez, Arancha, additional, Boss, Isaac W., additional, Gaudy, Allison, additional, Li, Shaoyi, additional, Hsu, Kevin, additional, Godwin, Colin D., additional, Burgess, Michael R., additional, San-Miguel, Jesús, additional, and Costa, Luciano J., additional

Published
2022
Full Text
View/download PDF

3. Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion

Author

Montefusco, Vittorio, primary, Cafro, Anna Maria, additional, Margiotta Casaluci, Gloria, additional, Patriarca, Francesca, additional, Mina, Roberto, additional, D'Agostino, Mattia, additional, Capra, Andrea, additional, Priola, Claudia, additional, Dalla Palma, Anna Benedetta, additional, Rizzi, Rita, additional, Genua, Angelo, additional, Petrucci, Maria Teresa, additional, Paris, Laura, additional, Belotti, Angelo, additional, Cavo, Michele, additional, Conticello, Concetta, additional, Carlo-Stella, Carmelo, additional, and Boccadoro, Mario, additional

Published
2022
Full Text
View/download PDF

4. Real-World Patterns of Utilization and Outcome of Market Approved Lenalidomide-Based Triplet Combinations in First Relapsed Multiple Myeloma Patients: Evidence from a Propensity Score Matched Analysis

Author

Mangiacavalli, Silvia, primary, Galli, Monica, additional, Pezzatti, Sara, additional, Belotti, Angelo, additional, Fazio, Francesca, additional, Marcatti, Magda, additional, Cafro, Anna Maria, additional, Mina, Roberto, additional, Zambello, Renato, additional, Paris, Laura, additional, Cartia, Claudio Salvatore, additional, Barilà, Gregorio, additional, Olivares, Cecilia, additional, Pompa, Alessandra, additional, Mazza, Rita, additional, Farina, Francesca, additional, Soldarini, Martina, additional, Benvenuti, Pietro, additional, Lecci, Marica, additional, Ferretti, Virginia Valeria, additional, and Petrucci, Maria Teresa, additional

Published
2021
Full Text
View/download PDF

5. Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Author

Pompa, Alessandra, primary, Conticello, Concetta, additional, Giannarelli, Diana, additional, Pettine, Loredana, additional, Paris, Laura, additional, Tognazzi, Lucia, additional, Marcatti, Magda, additional, Antonioli, Elisabetta, additional, Fioritoni, Francesca, additional, Bonalumi, Angela, additional, Mangiacavalli, Silvia, additional, Bertazzoni, Paola, additional, Vincelli, Iolanda Donatella, additional, Derudas, Daniele, additional, Siniscalchi, Agostina, additional, Pezzatti, Sara, additional, Zambello, Renato, additional, Citro, Annalisa, additional, Belotti, Angelo, additional, Lombardo, Alessandra, additional, Vozella, Federico, additional, Sementa, Adelina, additional, Consoli, Ugo, additional, Molteni, Alfredo, additional, Frungillo, Niccolò, additional, Gentile, Massimo, additional, Buda, Gabriele, additional, Aquino, Sara, additional, Palmieri, Salvatore, additional, Bongarzoni, Velia, additional, Inzoli, Alessandro, additional, Ferla, Valeria, additional, Rossi, Francesca Gaia, additional, Leotta, Valerio, additional, Romano, Alessandra, additional, Elia, Federica, additional, Del Fabro, Vittorio, additional, Montanaro, Guido, additional, Cavallaro, Francesca, additional, Galli, Monica, additional, and Baldini, Luca, additional

Published
2019
Full Text
View/download PDF

6. Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study

Author

Mangiacavalli, Silvia, Derudas, Daniele, Belotti, Angelo, Zamagni, Elena, Paris, Laura, Pavone, Vincenzo, Mina, Roberto, Di Renzo, Nicola, Fazio, Francesca, Tarantini, Giuseppe, Pezzatti, Sara, Palumbo, Gaetano, Marcatti, Magda, Vincelli, Jolanda Donatella, Cafro, Anna Maria, Falcone, Antonietta Pia, Zambello, Renato, Conticello, Concetta, Mazza, Rita, Di Raimondo, Francesco, Pompa, Alessandra, Martino, Enrica Antonia, Morabito, Fortunato, Stefanoni, Paola, Barila, Gregorio, Farina, Francesca, Cartia, Claudio Salvatore, Casson, Andrea, Ferretti, Virginia, Fresi, Eleonora, Arcaini, Luca, Petrucci, Maria Teresa, and Gentile, Massimo

Abstract

Background:Salvage autologous stem cell transplant (sASCT) has been indicated as possible therapeutic option at first (1 st) relapse, alternative to continuous treatment with novel agent combinations in selected Multiple Myeloma (MM) patients (pts). Particularly, MM pts who are eligible for a transplant procedure at the time of relapse and who have prolonged progression free survival (PFS) after the 1 stASCT - i.e. at least 36 or 18 months, respectively, with or without Lenalidomide (Len) maintenance - are those who could benefit most from sASCT. There are limited data regarding the frequency of choice for sASCT in the current therapeutic scenario and the outcome of sASCT when incorporating novel Len-based triplets KRd (Carfilzomib-Lenalidomide-Dexamethasone) and DaraRd (Daratumumab-Lenalidomide-Dexamethasone) as induction regimens before sASCT.

Published
2023
Full Text
View/download PDF

7. Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Author

Bar, Noffar, Mateos, Maria Victoria, Ribas, Paz, Hansson, Markus, Paris, Laura, Hofmeister, Craig C., Rodriguez Otero, Paula, Bermúdez, Maria Aranzazu, Martin, Thomas, Santoro, Armando, Yee, Andrew J., Creignou, Maria, Encinas Rodriguez, Cristina, Cerchione, Claudio, De La Rubia, Javier, Oriol, Albert, Waibel, Heidi, Besemer, Britta, Thompson, Ethan, Kiesel, Brian, Chen, Jinjie, Chung, Alexander, Boss, Isaac W., Gaudy, Allison, Li, Shaoyi, Hsu, Kevin, Godwin, Colin, Burgess, Michael R., San-Miguel, Jesús, and Costa, Luciano

Abstract

Introduction :

Published
2023
Full Text
View/download PDF

8. Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analysis

Author

Cavallaro, Gianluca, Galli, Monica, Paris, Laura, Stefanoni, Paola, Pavoni, Chiara, Mangiacavalli, Silvia, Masoni, Valeria, Palumbo, Michele, Pompa, Alessandra, Cafro, Anna Maria, Pezzatti, Sara, Crippa, Stefano, and Rambaldi, Alessandro

Abstract

Background

Published
2023
Full Text
View/download PDF

9. Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Author

D’Agostino, Mattia, Bertuglia, Giuseppe, Rota-Scalabrini, Delia, Belotti, Angelo, Morè, Sonia, Corradini, Paolo, Oliva, Stefania, Ledda, Antonio, Grasso, Mariella, Pavone, Vincenzo, Ronconi, Sonia, Vincelli, Iolanda Donatella, Ballanti, Stelvio, Velluti, Cristina, Cellini, Claudia, Gozzetti, Alessandro, Palmas, Angelo D., Gamberi, Barbara, Mancuso, Katia, Paris, Laura, Zambello, Renato, Petrucci, Maria Teresa, Bruno, Benedetto, Musto, Pellegrino, and Gay, Francesca

Abstract

•Amp(1q), HRCA ≥2, high CTC levels, and a longer time to reach first MRD negativity are significant predictors of unsustained MRD negativity.•Maintenance treatment with carfilzomib-lenalidomide reduces the risk of unsustained MRD negativity vs lenalidomide alone.

Published
2023
Full Text
View/download PDF

10. Invasive Fungal Infections (IFI) In Lymphoproliferative Disorders: Epidemiology, Outcome and Prognostic Factors

Author

Pioltelli, Maria Luisa, primary, Nosari, Annamaria, additional, Riva, Marta, additional, Marbello, Laura, additional, Paris, Laura, additional, Tedeschi, Alessandra, additional, Ricci, Francesca, additional, Vismara, Eleonora, additional, Valentina, Speziale, additional, Rusconi, Chiara, additional, Zilioli, Vittorio Ruggero, additional, Gabutti, Cristina, additional, Molteni, Alfredo, additional, Greco, Rosa, additional, Greco, Antonino, additional, Ravano, Emanuele, additional, and Morra, Enrica, additional

Published
2011
Full Text
View/download PDF

12. A Randomized Study of Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Cyclophosphamide-Dexamethasone Induction in Newly Diagnosed Myeloma Patients Eligible for Transplant: High Efficacy in High- and Standard-Risk Patients

Author

Gay, Francesca Maria, Rota Scalabrini, Delia, Belotti, Angelo, Galli, Monica, Zamagni, Elena, Offidani, Massimo, Oliva, Stefania, Montefusco, Vittorio, Zambello, Renato, Ledda, Antonio, Grasso, Mariella, Aquino, Sara, Esma, Fabrizio, Tosi, Patrizia, Pisani, Francesco, Annibali, Ombretta, Liberati, Anna Marina, Baraldi, Anna, Galieni, Piero, Specchia, Giorgina, Pescosta, Norbert, Mancuso, Katia, Paris, Laura, Ribolla, Rossella, Coha, Valentina, Palumbo, Antonio, Musto, Pellegrino, Cavo, Michele, and Boccadoro, Mario

Published
2017
Full Text
View/download PDF

13. Effect of Proteasome Inhibitors and/or Immunomodulatory Drugs on the Risk of Early Death of 991 Newly Diagnosed Symptomatic Multiple Myeloma Patients: A Single Centre Retrospective Analysis

Author

Galli, Monica, Paris, Laura, Pavoni, Chiara, Delaini, Federica, and Rambaldi, Alessandro

Abstract

Introduction and aim: Several clinical trials have shown that the incorporation of novel agents (i.e., proteasome inhibitor, bortezomib and immunomodulatory drugs, thalidomide and lenalidomide) in the treatment of newly diagnosed symptomatic multiple myeloma (MM) patients improves their time to first response and survival outcomes. Nevertheless, some patients still die within 3 months (early death, ED) from starting treatment. Thus, we investigated the effect of novel agents- containing first line treatments on the risk of ED of MM patients.

Published
2017
Full Text
View/download PDF

14. Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.

Author

D'Agostino M, Bertuglia G, Rota-Scalabrini D, Belotti A, Morè S, Corradini P, Oliva S, Ledda A, Grasso M, Pavone V, Ronconi S, Vincelli ID, Ballanti S, Velluti C, Cellini C, Gozzetti A, Palmas AD, Gamberi B, Mancuso K, Paris L, Zambello R, Petrucci MT, Bruno B, Musto P, and Gay F

Subjects
Humans, Lenalidomide therapeutic use, Treatment Outcome, Neoplasm, Residual, Prognosis, Multiple Myeloma drug therapy
Abstract

Abstract: The prognostic impact of achieving and in particular maintaining measurable residual disease (MRD) negativity in multiple myeloma is now established; therefore, identifying among MRD-negative patients the ones at higher risk of losing MRD negativity is of importance. We analyzed predictors of unsustained MRD negativity in patients enrolled in the FORTE trial (NCT02203643). MRD was performed by multiparameter flow cytometry (sensitivity of 10-5) at premaintenance and every 6 months thereafter. The cumulative incidence (CI) of MRD resurgence and/or progression was analyzed in MRD-negative patients. A total of 306 of 474 (65%) MRD-negative patients were analyzed. After a median follow-up of 50.4 months from MRD negativity, 185 of 306 (60%) patients were still MRD negative and progression free, 118 (39%) lost their MRD-negative status, and 3 patients (1%) died without progression. Amp1q vs normal (4-year CI, 63% vs 34), ≥2 concomitant high-risk cytogenetic abnormalities vs 0 (4-year CI, 59% vs 33%), circulating tumor cells at baseline (high vs low at 4-year CI, 62% vs 32%), and time-to-reach MRD negativity postconsolidation vs preconsolidation (4-year CI, 46% vs 35%) were associated with a higher risk of unsustained MRD negativity in a multivariate Fine-Gray model. During the first 2 years of maintenance, patients receiving carfilzomib-lenalidomide vs lenalidomide alone had a lower risk of unsustained MRD negativity (4-year CI, 20% vs 33%)., (© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results